Triptolide inhibits amyloid-β production and protects neural cells by inhibiting CXCR2 activity

Journal of Alzheimer's Disease

Volumn 33, Issue 1, 2013, Pages 217-229

  Wang, Ju ^a   Shi, Zi Qi ^a   Xu, Xiaojun ^a   Xin, Gui Zhong ^a   Chen, Jun ^a   Qi, Lian Wen ^a   Li, Ping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; amyloid ; CXCR2; neuroprotective; triptolide; secretase

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CHEMOKINE RECEPTOR CXCR2; NOTCH RECEPTOR; TRIPTOLIDE;

ARTICLE; BRAIN CELL; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; HUMAN; HUMAN CELL; IC 50; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84872445015     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120841     Document Type: Article

References (51)

1. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399, A23-A31.
2. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
3. Liu Q (2011) Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 11, 377-383.
4. Gong Y, Xue B, Jiao J, Jing L, Wang X (2008) Triptolide inhibits COX-2 expression and PGE2 release by suppressing the activity of NF-kappaB and JNK in LPS-treated microglia. J Neurochem 107, 779-788.
5. Su Z, Yuan Y, Cao L, Zhu Y, Gao L, Qiu Y, He C (2010) Triptolide promotes spinal cord repair by inhibiting astrogliosis and inflammation. Glia 58, 901-915.
6. Kizelsztein P, Komarnytsky S, Raskin I (2009) Oral administration of triptolide ameliorates the clinical signs of experimental autoimmune encephalomyelitis (EAE) by induction of HSP70 and stabilization of NF-kappaB/IkappaBalpha transcriptional complex. J Neuroimmunol 217, 28-37.
7. Zhou HF, Liu XY, Niu DB, Li FQ, He QH,Wang XM (2005) Triptolide protects dopaminergic neurons from inflammationmediated damage induced by lipopolysaccharide intranigral injection. Neurobiol Dis 18, 441-449.
8. Jiao J, Xue B, Zhang L, Gong Y, Li K,Wang H, Jing L, Xie J, Wang X (2008) Triptolide inhibits amyloid-beta1-42-induced TNF-alpha and IL-1beta production in cultured rat microglia. J Neuroimmunol 205, 32-36.
9. Zhou HF, Niu DB, Xue B, Li FQ, Liu XY, He QH,Wang XH, WangXM(2003)Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures. Neuroreport 14, 1091-1095. (Pubitemid 36829797)
10. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ (2010) Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 7, 17.
11. Gangur V, Birmingham NP, Thanesvorakul S (2002) Chemokines in health and disease. Vet Immunol Immunopathol 86, 127-136. (Pubitemid 34465743)
12. Le Y, Zhou Y, Iribarren P, Wang J (2004) Chemokines and chemokine receptors: Their manifold roles in homeostasis and disease. Cell Mol Immunol 1, 95-104.
13. Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G (2001) Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 22, 147-184. (Pubitemid 32706335)
14. Xia MQ, Hyman BT (1999) Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 5, 32-41. (Pubitemid 29051876)
15. Xia M, Qin S, McNamara M, Mackay C, Hyman BT (1997) Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer's disease. Am J Pathol 150, 1267-1274. (Pubitemid 27152645)
16. Thirumangalakudi L, Yin L, Rao HV, Grammas P (2007) IL-8 induces expression of matrix metalloproteinases, cell cycle and pro-apoptotic proteins, and cell death in cultured neurons. J Alzheimers Dis 11, 305-311. (Pubitemid 47094028)
17. Liu YJ, Guo DW, Tian L, Shang DS, Zhao WD, Li B, Fang WG, Zhu L, Chen YH (2010) Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiol Aging 31, 175-188.
18. Kerstetter AE, Padovani-Claudio DA, Bai L, Miller RH (2009) Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis. Exp Neurol 220, 44-56.
19. Bakshi P, Margenthaler E, Laporte V, Crawford F, Mullan M (2008) Novel role of CXCR2 in regulation of gammasecretase activity. ACS Chem Biol 3, 777-789.
20. Bakshi P, Margenthaler E, Reed J, Crawford F, Mullan M (2011) Depletion of CXCR2 inhibits gamma-secretase activity and amyloid-beta production in a murine model of Alzheimer's disease. Cytokine 53, 163-169.
21. Chin J, Adams AD, Bouffard A, Green A, Lacson RG, Smith T, Fischer PA, Menke JG, Sparrow CP, Mitnaul LJ (2003) Miniaturization of cell-based beta-lactamasedependent FRET assays to ultra-high throughput formats to identify agonists of human liver X receptors. Assay Drug Dev Technol 1, 777-787.
22. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE, Sarau HM (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273, 10095-10098. (Pubitemid 28227606)
23. DoveyHF, JohnV, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD, Audia JE (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76, 173-181. (Pubitemid 32044380)
24. Wolfe MS (2008) Inhibition and modulation of gammasecretase for Alzheimer's disease. Neurotherapeutics 5, 391-398. (Pubitemid 351952492)
25. Selkoe D, Mandelkow E, Holtzman D (2012) Deciphering Alzheimer disease. Cold Spring Harb Perspect Med 2, a011460.
26. Selkoe DJ (1991) Amyloid protein and Alzheimer's disease. Sci Am 265, 68-71, 74-76, 78.
27. Selkoe DJ (1994) Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 10, 373-403. (Pubitemid 24372824)
28. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766. (Pubitemid 32267077)
29. McGeer PL, Rogers J, McGeerEG(2006) Inflammation, antiinflammatory agents and Alzheimer disease: The last 12 years. J Alzheimers Dis 9, 271-276. (Pubitemid 44253320)
30. Rogers J,Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B,Walker D, McGeer P (1996) Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 17, 681-686. (Pubitemid 26348868)
31. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M (1999) Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286, 2352-2355. (Pubitemid 30016899)
32. Tan J,TownT, Crawford F, MoriT, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 5, 1288-1293. (Pubitemid 35417763)
33. Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K, Verbeeck C, Yager D, Eckman C, Ye W, Sagi S, Cottrell BA, Torpey J, Rosenberry TL, Fauq A, Wolfe MS, Schmidt B,Walsh DM, Koo EH, Golde TE (2008) Substrate-targeting gamma-secretase modulators. Nature 453, 925-929.
34. Wyss-Coray T (2006) Inflammation in Alzheimer disease: Driving force, bystander or beneficial response. Nat Med 12, 1005-1015. (Pubitemid 44353380)
35. Mines M, Ding Y, Fan GH (2007) The many roles of chemokine receptors in neurodegenerative disorders: Emerging new therapeutical strategies. Curr Med Chem 14, 2456-2470. (Pubitemid 47618034)
36. Kumar A, Takada Y, Boriek AM, Aggarwal BB (2004) Nuclear factor-kappaB: Its role in health and disease. J Mol Med (Berl) 82, 434-448. (Pubitemid 39044283)
37. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG, Waugh DJ (2007) HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 26, 7333-7345. (Pubitemid 350115971)
38. Wang B, Khachigian LM, Esau L, Birrer MJ, Zhao X, Parker MI, Hendricks DT (2009) A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancer. Mol Cancer Res 7, 755-764.
39. Nguyen-Jackson H, Panopoulos AD, Zhang H, Li HS, Watowich SS (2010) STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSFinduced CXCR2 expression and via modulation of CXCR2 signal transduction. Blood 115, 3354-3363.
40. Wang Z, Jin H, Xu R, Mei Q, Fan D (2009) Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med 41, 717-727.
41. Li Y, Yu C, Zhu WM, Xie Y, Qi X, Li N, Li JS (2010) Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17. Mol Immunol 47, 2467-2474.
42. Cataisson C, Pearson AJ, Tsien MZ, Mascia F, Gao JL, Pastore S,YuspaSH(2006)CXCR2ligands and G-CSF mediate PKCalpha-induced intraepidermal inflammation. J Clin Invest 116, 2757-2766. (Pubitemid 44511639)
43. Martin D, Galisteo R, Gutkind JS (2009) CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284, 6038-6042.
44. Seaton A, Maxwell PJ, Hill A, Gallagher R, Pettigrew J, Wilson RH, Waugh DJ (2009) Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrateresistant prostate cancer cells. Br J Cancer 101, 1620-1629.
45. Franciosi S, Choi HB, Kim SU, McLarnon JG (2005) IL-8 enhancement of amyloid-beta (Abeta 1-42)-induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. J Neuroimmunol 159, 66-74. (Pubitemid 40126178)
46. Limatola C, Mileo AM, Giovannelli A, Vacca F, Ciotti MT, Mercanti D, Santoni A, Eusebi F (1999) The growth-related gene product beta induces sphingomyelin hydrolysis and activation of c-Jun N-terminal kinase in rat cerebellar granule neurones. J Biol Chem 274, 36537-36543.
47. Johnson EA, Dao TL, Guignet MA, Geddes CE, Koemeter-Cox AI, Kan RK (2011) Increased expression of the chemokines CXCL1 and MIP-1alpha by resident brain cells precedes neutrophil infiltration in the brain following prolonged soman-induced status epilepticus in rats. J Neuroinflammation 8, 41.
48. Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, Romero IA, Weksler B, Stanimirovic DB, Zhang W (2009) Expression of inflammatory genes induced by betaamyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 34, 95-106.
49. Xia M, HymanBT(2002)GROalpha/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation - a role in Alzheimer's disease. J Neuroimmunol 122, 55-64. (Pubitemid 34075490)
50. Yang RH, Strong JA, Zhang JM (2009) NF-kappaB mediated enhancement of potassium currents by the chemokine CXCL1/growth related oncogene in small diameter rat sensory neurons. Mol Pain 5, 26.
51. Wang JG, Strong JA, XieW, Yang RH, Coyle DE,Wick DM, Dorsey ED, ZhangJM(2008) The chemokine CXCL1/growth related oncogene increases sodium currents and neuronal excitability in small diameter sensory neurons. Mol Pain 4, 38.